Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years old, any gender
• People who are willing to take part and have signed a consent form (either themselves or through a legal guardian)
• People who have been diagnosed with T-cell lymphoma according to specific recognised medical guidelines
• People whose T-cell lymphoma has come back after treatment or has not responded to treatment — meaning either the cancer did not go into full remission after initial treatment, or it returned with signs of disease in the blood, bone marrow, or other areas of the body
• People who have not received antibody-based therapy in the 2 weeks before the cell therapy is given
• People who are reasonably active and able to carry out daily activities (measured by a standard medical scoring system called ECOG, with a score of 0 to 2)
• People who are able to undergo a blood-filtering procedure called apheresis, which collects cells from the blood
• People who are expected to live for more than 3 months

Who may not be able to join:

• People who have had an allergic reaction to any ingredient used in the cell therapy product
• People whose blood test results show certain concerning levels, including high bilirubin, high liver enzyme levels (ALT or AST), high creatinine, or very low platelet counts
• People with significant heart failure classified as class III or IV, or whose heart pumping function (measured by an ultrasound of the heart) is below 50%
• People with poor lung function or blood oxygen levels below 92% while breathing normal room air
• People who have had a heart attack, heart procedure (such as angioplasty or stenting), unstable chest pain, or another serious heart condition within the past 12 months
• People with severe high blood pressure that cannot be controlled with medication
• People who currently have another advanced cancer (though people whose other cancer has been treated and is considered stable may still be considered)
• People with a history of serious head injury, loss of consciousness, epilepsy, or significant stroke or brain bleeding
• People with active leukemia affecting the central nervous system (brain and spinal cord) that is resistant to certain treatments, or who are currently receiving radiation to the head or spine (those with a previous history that has been successfully treated may still be considered — confirm with trial site)
• People with autoimmune diseases, immune system disorders, or those who need medications that suppress the immune system
• People who currently have an active, uncontrolled infection
• People who have previously received any CAR-T cell therapy or other genetically modified T cell therapy
• People who have received a live vaccine within 4 weeks before joining the trial
• People with HIV, hepatitis B (HBV), hepatitis C (HCV), or syphilis infections, including those who carry hepatitis B without symptoms
• People with a history of alcohol dependence, drug addiction, or mental illness
• People who have taken part in another clinical trial within the 3 months before joining this study
• Women who are pregnant or breastfeeding, who plan to become pregnant during the trial, or who are able to become pregnant but are unable to use effective contraception
• People whom the trial doctors consider unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.